Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$13 Mln
P/E Ratio
1.52
P/B Ratio
7.42
Industry P/E
--
Debt to Equity
-0.01
ROE
-13.58 %
ROCE
-2590.18 %
Div. Yield
0 %
Book Value
--
EPS
3304.94
CFO
$-220.04 Mln
EBITDA
$-282.86 Mln
Net Profit
$-301.54 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
PAVmed (PAVM)
| 16.16 | -2.81 | 13.20 | -57.62 | -65.47 | -53.35 | -- |
|
BSE Sensex*
| 2.73 | 3.83 | 4.72 | 7.65 | 12.10 | 19.69 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
PAVmed (PAVM)
| -84.53 | -42.78 | -80.49 | 16.04 | 76.67 | 24.74 | -57.71 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.69 | 10,202.62 | 12.01 | 12.69 | |
| 72.33 | 10,025.34 | 96.83 | 2.52 | |
| 163.14 | 8,863.93 | -- | -25.23 | |
| 296.91 | 11,513.99 | 277.87 | 3.65 |
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for... use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York Address: 360 Madison Avenue, New York, NY, United States, 10017 Read more
Chairman & CEO
Dr. Lishan Aklog M.D.
Chairman & CEO
Dr. Lishan Aklog M.D.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of PAVmed Inc (PAVM) stood at $ 30,660 Mln as on 31-Dec-24
The share price of PAVmed Inc (PAVM) is $0.73 (NASDAQ) as of 29-Apr-2025 16:00 EDT. PAVmed Inc (PAVM) has given a return of -65.47% in the last 3 years.
PAVmed Inc (PAVM) has a market capitalisation of $ 13 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of PAVmed Inc (PAVM) is 1.52 times as on 28-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the PAVmed Inc (PAVM) and enter the required number of quantities and click on buy to purchase the shares of PAVmed Inc (PAVM).
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York Address: 360 Madison Avenue, New York, NY, United States, 10017
The CEO & director of Dr. Lishan Aklog M.D.. is PAVmed Inc (PAVM), and CFO & Sr. VP is Dr. Lishan Aklog M.D..
There is no promoter pledging in PAVmed Inc (PAVM).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,078
|
|
|
1,054
|
|
|
964
|
|
|
853
|
| PAVmed Inc. (PAVM) | Ratios |
|---|---|
|
Return on equity(%)
|
-2508.29
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
1067.31
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of PAVmed Inc (PAVM) was $0 Mln.
$0.01
(
